LC003465

### 2024 -- S 2076

# STATE OF RHODE ISLAND

### IN GENERAL ASSEMBLY

### JANUARY SESSION, A.D. 2024

## AN ACT

### RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES

Introduced By: Senators Lawson, Lauria, Euer, Britto, Pearson, Gallo, Miller, DiMario, Bissaillon, and Cano Date Introduced: January 12, 2024

Referred To: Senate Health & Human Services

It is enacted by the General Assembly as follows:

1 SECTION 1. Section 27-18-90 of the General Laws in Chapter 27-18 entitled "Accident

2 and Sickness Insurance Policies" is hereby amended to read as follows:

- 3 27-18-90. Mandatory coverage for treatment of pediatric autoimmune
- 4 <u>neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset</u>
- 5 <u>neuropsychiatric syndrome. [Expires December 31, 2025.]</u> Mandatory coverage for treatment

6 of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections

7 and pediatric acute onset neuropsychiatric syndrome.

8 (a) Every group health insurance contract, or every group hospital or medical expense 9 insurance policy, plan, or group policy delivered, issued for delivery, or renewed in this state, by 10 any health insurance carrier, on or after January 1, 2023, shall provide coverage for treatment of 11 pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and 12 pediatric acute onset neuropsychiatric syndrome, including, but not limited to, the use of 13 intravenous immunoglobin therapy.

(b) For billing and diagnosis purposes, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome shall be coded as autoimmune encephalitis until the American Medical Association and the Centers for Medicare and Medicaid Services create and assign a specific code for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome. Thereafter, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome may
 be coded as autoimmune encephalitis, pediatric autoimmune neuropsychiatric disorders associated
 with streptococcal infections, or pediatric acute onset neuropsychiatric syndrome.

4 (c) The healthcare benefits outlined in this section apply only to services delivered within
5 the state of Rhode Island; provided, that all health insurance carriers shall be required to provide
6 coverage for those benefits mandated by this section outside of the state of Rhode Island where it
7 can be established through a pre-authorization process that the required services are not available
8 in the state of Rhode Island from a provider in the health insurance carrier's network.

9 (d) Each health insurance carrier shall collect and provide to the office of the health 10 insurance commissioner, in a form and frequency acceptable to the commissioner, information and 11 data reflecting the costs and the savings of adding the benefit coverage provided in this section. On 12 or before January 1, 2025, the office of the health insurance commissioner shall report to the general 13 assembly a cost-benefit analysis of the implementation of the benefit coverage provided in this 14 section. The intent of this cost-benefit analysis is to determine if adding the benefit coverage 15 provided in this section produces a net savings to health insurance carriers and to policy holders.

16

## (e) This section shall sunset and be repealed effective December 31, 2025.

SECTION 2. Section 27-19-82 of the General Laws in Chapter 27-19 entitled "Nonprofit
Hospital Service Corporations" is hereby amended to read as follows:

19 <u>27-19-82. Mandatory coverage for treatment of pediatric autoimmune</u>

20 <u>neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset</u>

21 <u>neuropsychiatric syndrome. [Expires December 31, 2025.]</u> Mandatory coverage for treatment

22 of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections

23 and pediatric acute onset neuropsychiatric syndrome.

(a) Every group health insurance contract, or every group hospital or medical expense insurance policy, plan, or group policy delivered, issued for delivery, or renewed in this state, by any health insurance carrier, on or after January 1, 2023, shall provide coverage for treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome, including, but not limited to, the use of intravenous immunoglobin therapy.

30 (b) For billing and diagnosis purposes, pediatric autoimmune neuropsychiatric disorders 31 associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome shall 32 be coded as autoimmune encephalitis until the American Medical Association and the Centers for 33 Medicare & Medicaid Services create and assign a specific code for pediatric autoimmune 34 neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset

1 neuropsychiatric syndrome. Thereafter, pediatric autoimmune neuropsychiatric disorders 2 associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome may 3 be coded as autoimmune encephalitis, pediatric autoimmune neuropsychiatric disorders associated 4 with streptococcal infections, or pediatric acute onset neuropsychiatric syndrome.

5 (c) The healthcare benefits outlined in this section apply only to services delivered within the state of Rhode Island; provided, that all health insurance carriers shall be required to provide 6 7 coverage for those benefits mandated by this section outside of the state of Rhode Island where it 8 can be established through a pre-authorization process that the required services are not available 9 in the state of Rhode Island from a provider in the health insurance carrier's network.

10 (d) Each health insurance carrier shall collect and provide to the office of the health 11 insurance commissioner, in a form and frequency acceptable to the commissioner, information and 12 data reflecting the costs and the savings of adding the benefit coverage provided in this section. On 13 or before January 1, 2025, the office of the health insurance commissioner shall report to the general 14 assembly a cost-benefit analysis of the implementation of the benefit coverage provided in this 15 section. The intent of this cost-benefit analysis is to determine if adding the benefit coverage 16 provided in this section produces a net savings to health insurance carriers and to policyholders.

17 (e) This section shall sunset and be repealed effective December 31, 2025.

18 SECTION 3. Section 27-20-78 of the General Laws in Chapter 27-20 entitled "Nonprofit 19 Medical Service Corporations" is hereby amended to read as follows:

20

27-20-78. Mandatory coverage for treatment of pediatric autoimmune

21 neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset

22 neuropsychiatric syndrome. [Expires December 31, 2025.] Mandatory coverage for treatment

23 of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections

#### 24 and pediatric acute onset neuropsychiatric syndrome.

25 (a) Every group health insurance contract, or every group hospital or medical expense 26 insurance policy, plan, or group policy delivered, issued for delivery, or renewed in this state, by any health insurance carrier, on or after January 1, 2023, shall provide coverage for treatment of 27 28 pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and 29 pediatric acute onset neuropsychiatric syndrome, including, but not limited to, the use of 30 intravenous immunoglobin therapy.

31 (b) For billing and diagnosis purposes, pediatric autoimmune neuropsychiatric disorders 32 associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome shall 33 be coded as autoimmune encephalitis until the American Medical Association and the Centers for 34 Medicare & Medicaid Services create and assign a specific code for pediatric autoimmune

neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome. Thereafter, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome may be coded as autoimmune encephalitis, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, or pediatric acute onset neuropsychiatric syndrome.

6 (c) The healthcare benefits outlined in this section apply only to services delivered within 7 the state of Rhode Island; provided, that all health insurance carriers shall be required to provide 8 coverage for those benefits mandated by this section outside of the state of Rhode Island where it 9 can be established through a pre-authorization process that the required services are not available 10 in the state of Rhode Island from a provider in the health insurance carrier's network.

(d) Each health insurance carrier shall collect and provide to the office of the health insurance commissioner, in a form and frequency acceptable to the commissioner, information and data reflecting the costs and the savings of adding the benefit coverage provided in this section. On or before January 1, 2025, the office of the health insurance commissioner shall report to the general assembly a cost-benefit analysis of the implementation of the benefit coverage provided in this section. The intent of this cost-benefit analysis is to determine if adding the benefit coverage provided in this section produces a net savings to health insurance carriers and to policyholders.

18 (e) This section shall sunset and be repealed effective December 31, 2025.

- SECTION 4. Section 27-41-95 of the General Laws in Chapter 27-41 entitled "Health
   Maintenance Organizations" is hereby amended to read as follows:
- 21 <u>27-41-95.</u> <u>Mandatory coverage for treatment of pediatric autoimmune</u>

22 <u>neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset</u>

23 <u>neuropsychiatric syndrome. [Expires December 31, 2025.]</u> Mandatory coverage for treatment

24 of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections

- 25 and pediatric acute onset neuropsychiatric syndrome.
- (a) Every group health insurance contract, or every group hospital or medical expense insurance policy, plan, or group policy delivered, issued for delivery, or renewed in this state, by any health insurance carrier, on or after January 1, 2023, shall provide coverage for treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome, including, but not limited to, the use of intravenous immunoglobin therapy.

(b) For billing and diagnosis purposes, pediatric autoimmune neuropsychiatric disorders
 associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome shall
 be coded as autoimmune encephalitis until the American Medical Association and the Centers for

Medicare & Medicaid Services create and assign a specific code for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome. Thereafter, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome may be coded as autoimmune encephalitis, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, or pediatric acute onset neuropsychiatric syndrome.

(c) The healthcare benefits outlined in this section apply only to services delivered within
the state of Rhode Island; provided, that all health insurance carriers shall be required to provide
coverage for those benefits mandated by this section outside of the state of Rhode Island where it
can be established through a pre-authorization process that the required services are not available
in the state of Rhode Island from a provider in the health insurance carrier's network.

12 (d) Each health insurance carrier shall collect and provide to the office of the health 13 insurance commissioner, in a form and frequency acceptable to the commissioner, information and 14 data reflecting the costs and the savings of adding the benefit coverage provided in this section. On 15 or before January 1, 2025, the office of the health insurance commissioner shall report to the general 16 assembly a cost-benefit analysis of the implementation of the benefit coverage provided in this 17 section. The intent of this cost-benefit analysis is to determine if adding the benefit coverage 18 provided in this section produces a net savings to health insurance carriers and to policyholders. 19 (e) This section shall sunset and be repealed effective December 31, 2025.

20

(c) This section shall subset and be repeated effective Determoter ST

SECTION 5. This act shall take effect upon passage.

LC003465

### EXPLANATION

### BY THE LEGISLATIVE COUNCIL

### OF

# AN ACT

# RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES

\*\*\*

This act would remove the sunset provision of all statutory laws requiring coverage for the
 treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal
 infections and pediatric acute onset neuropsychiatric syndrome, thus requiring continued insurance
 coverage beyond December 31, 2025
 This act would take effect upon passage.

LC003465